SecSonar.com

Fennec Pharmaceuticals Inc. (FENC)

Fennec Pharmaceuticals Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Fennec Pharmaceuticals Inc. (FENC) is a Biotechnology company based in US with a market capitalization of $284.4M. Revenue declined 6.1% year-over-year and free cash flow was negative at -$12.5M. This page tracks FENC's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 32 employees · IPO Sep 15, 2017

Valuation

Valuation & price

$9.75 · as of May 17, 2026 · -11.6% vs 52w high

—

P/E ratio

Latest-FY diluted EPS

8.11

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$11.02$8.46$5.91Jul 25Dec 25Jul 26Jul 7, 25$8.47Jul 9, 25$8.89Jul 11, 25$8.78Jul 15, 25$8.71Jul 17, 25$8.75Jul 21, 25$8.41Jul 23, 25$8.73Jul 25, 25$8.63Jul 29, 25$8.54Jul 31, 25$8.18Aug 4, 25$8.32Aug 6, 25$8.16Aug 11, 25$8.25Aug 13, 25$9.11Aug 15, 25$8.36Aug 19, 25$7.91Aug 21, 25$8.17Aug 25, 25$8.65Aug 27, 25$9.04Aug 29, 25$8.87Sep 3, 25$8.86Sep 5, 25$9.00Sep 9, 25$9.22Sep 11, 25$9.03Sep 16, 25$8.85Sep 18, 25$8.93Sep 22, 25$8.67Sep 24, 25$8.40Sep 26, 25$9.04Sep 30, 25$9.36Oct 2, 25$9.67Oct 6, 25$9.74Oct 8, 25$9.22Oct 10, 25$8.57Oct 14, 25$8.28Oct 16, 25$8.64Oct 21, 25$8.72Oct 23, 25$8.96Oct 27, 25$8.82Oct 29, 25$8.47Oct 31, 25$8.20Nov 4, 25$8.00Nov 6, 25$8.00Nov 10, 25$7.68Nov 12, 25$7.78Nov 14, 25$7.86Nov 18, 25$8.75Nov 20, 25$7.84Nov 25, 25$7.95Nov 28, 25$8.19Dec 2, 25$7.61Dec 4, 25$7.78Dec 8, 25$7.54Dec 10, 25$7.44Dec 12, 25$7.55Dec 16, 25$7.62Dec 18, 25$7.58Dec 22, 25$7.69Dec 24, 25$7.67Dec 29, 25$7.69Jan 2, 26$7.68Jan 6, 26$7.38Jan 8, 26$7.58Jan 12, 26$7.62Jan 14, 26$7.58Jan 16, 26$7.59Jan 21, 26$7.70Jan 23, 26$7.66Jan 27, 26$7.85Jan 29, 26$7.52Feb 2, 26$7.83Feb 4, 26$7.94Feb 9, 26$7.86Feb 11, 26$7.82Feb 13, 26$8.42Feb 18, 26$8.97Feb 20, 26$8.74Feb 24, 26$8.91Feb 26, 26$8.61Mar 2, 26$8.22Mar 4, 26$8.20Mar 6, 26$7.70Mar 10, 26$7.89Mar 12, 26$7.63Mar 17, 26$7.76Mar 19, 26$7.65Mar 23, 26$7.45Mar 25, 26$6.17Mar 27, 26$5.91Mar 31, 26$6.15Apr 2, 26$6.42Apr 7, 26$6.32Apr 9, 26$6.40Apr 13, 26$5.93Apr 15, 26$6.50Apr 17, 26$6.79Apr 22, 26$6.68Apr 24, 26$6.84Apr 28, 26$6.70Apr 30, 26$6.49May 4, 26$6.65May 6, 26$7.18May 8, 26$6.93May 12, 26$7.03May 14, 26$9.24May 18, 26$9.60May 20, 26$9.75May 22, 26$9.93May 28, 26$9.89Jun 1, 26$9.88Jun 3, 26$9.14Jun 5, 26$8.70Jun 9, 26$8.77Jun 11, 26$8.85Jun 15, 26$9.19Jun 17, 26$8.98Jun 22, 26$9.53Jun 24, 26$10.40Jun 26, 26$11.02Jul 2, 26$10.70
$5.7752-week range$11.03
Loading valuation history…

Fundamentals

Key fundamentals

$284.4M

Market cap

-6.1%

Revenue growth (YoY)

91.6%

Gross margin

-$12.5M

Free cash flow (USD)

-$36.7M

Net debt

Net cash position

4.7%

Share dilution

1/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2016 → 2025

FY 2016$0.00FY 2017$0.00FY 2018$0.00FY 2019$0.00FY 2020$170.0KFY 2021$0.00FY 2022$1.5MFY 2023$21.3MFY 2024$47.5MFY 2025$44.6M
$0$44.6M

Free cash flow by year

2016 → 2025

FY 2016$-2.1MFY 2017$-3.6MFY 2018$-7.8MFY 2019$-9.1MFY 2020$-15.6MFY 2021$-14.2MFY 2022$-18.1MFY 2023$-17.1MFY 2024$27.0MFY 2025$-12.5M
-$2.1M-$12.5M

Gross margin by year

2022 → 2025

FY 202294.4%FY 202394.1%FY 202493.3%FY 202591.6%
94.4%91.6%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

3

Insider sells · 90 days

Earnings

Last reported: May 14, 2026 (EPS $0.01)

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • 8-K eventAnnual Meeting ResultsJun 10, 2026Filing
  • Insider sellInsider Sell $94K · 10b5-1 PlanRaykov Rosty · Director · $93.8KJun 2, 2026Filing
  • 8-K eventResearch Presentation at ASCOMay 22, 2026Filing
  • 8-K eventStock Option GrantsMay 18, 2026Filing
  • Quarterly report10-Q FiledMay 14, 2026Filing
  • Insider sellInsider Sell $59K · 10b5-1 PlanRALLIS CHRIS A · Director · $58.8KMay 12, 2026Filing
  • Insider sellInsider Sell $70K · 10b5-1 PlanRaykov Rosty · Director · $69.8KMay 1, 2026Filing
  • 8-K eventDirector RetirementApr 28, 2026Filing
  • 8-K eventAbstracts Accepted for ASCOApr 22, 2026Filing
  • 8-K eventInvestigator-Sponsored Study InitiatedApr 7, 2026Filing

Questions

Frequently asked questions

What is Fennec Pharmaceuticals Inc.'s market cap?

Fennec Pharmaceuticals Inc. (FENC) has a market capitalization of $284.4M.

What is FENC's P/E ratio?

A meaningful P/E ratio is not available for FENC — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

What is FENC's price-to-book (P/B) ratio?

FENC trades at 8.11 times book value per share.

When did Fennec Pharmaceuticals Inc. last report earnings?

FENC last reported earnings on May 14, 2026; the next date is not yet scheduled.

Are insiders buying FENC stock?

SEC Form 4 filings show no open-market insider buys at Fennec Pharmaceuticals Inc. in the last 90 days (3 sells).

Same arena

Related companies in Biotechnology

STTK

Shattuck Labs, Inc.

$285M

ACIU

AC Immune S.A.

$281.4M

AKBA

Akebia Therapeutics, Inc.

$280.3M

ZNTL

Zentalis Pharmaceuticals, Inc.

$290.7M

TRDA

Entrada Therapeutics, Inc.

$272.5M

ALT

Altimmune, Inc.

$270.9M

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.